FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)

ABSTRACT: This Phase 1 study will evaluate the safety and tolerability of [Ga-68]-PNT6555 and [Lu-177]-PNT6555 in subjects with select solid tumors that have FAP over-expression, in order to determine a recommended Phase 2 dose.

DISEASE(S): Squamous Cell Carcinoma Of Head And Neck,Sarcoma,Esophageal Neoplasms,Melanoma,Colorectal Cancer,Esophageal Cancer,Soft Tissue Sarcoma,Melanoma (skin),Head And Neck Squamous Cell Carcinoma,Pancreatic Ductal Adenocarcinoma,Cholangiocarcinoma

PROVIDER: 2736832 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR